BPC-157, TB-500, MK-677: What the Peptide Hype Leaves Out — A Coach's Safety Brief

How we sourced this. Every claim below is tied to a named study — a systematic review, a randomised trial, or the live trial registry — and linked. We graded the evidence and, just as importantly, flagged where it’s absent. This is coaching and safety information, not medical advice, and nothing here is an endorsement to use any of these substances — several are unapproved drugs. Last updated 9 October 2026.

First, which “peptides” we’re talking about

The word “peptides” is doing two completely different jobs in fitness, and the confusion is doing real harm. On one side: collagen peptides and whey peptides — food-derived protein fragments in a supplement tub, safe, legal, well-studied, and covered elsewhere on Sqwod. On the other, and the subject of this piece: a family of injectable “research-chemical” peptides — BPC-157, TB-500 (thymosin beta-4), and the growth-hormone peptides CJC-1295, ipamorelin and MK-677 — sold in vials through grey-market websites and passed around gym group chats as healing-and-growth shortcuts. Everything below is about that second group. If your client means the tub, relax; if they mean the vial, read on.

We pulled the human evidence for each, and the recurring finding wasn’t danger so much as emptiness — the studies people assume exist mostly don’t. That absence is the story, and it’s exactly what a coach needs to be able to explain calmly.

BPC-157: the flagship that’s almost all animal

BPC-157 — “Body Protection Compound” — is the one your clients will name first, usually as a miracle tendon-and-gut healer. Here’s the honest state of it. A 2025 systematic review from an orthopaedic sports-medicine group set out to gather everything and found 36 studies: 35 of them preclinical (animal and cell), and exactly one small human study.¹ That one study deserves a closer look, because it’s the entire human evidence base for the use people buy it for: a retrospective chart review from a private hormone clinic in Florida, in which 17 knee-pain patients who’d had BPC-157 (12 of them BPC-157 alone, 4 with thymosin beta-4 added) injected into the joint were phoned up to a year later and asked whether it helped. Sixteen were reached; fourteen said yes. There was no control group, no imaging, no validated pain or function score, and the follow-up was a phone call.¹² That is the whole of it. The reviewers were blunt that there were no clinical safety data at all, and that adverse effects are plausible precisely because the manufacturing is unregulated.¹ A separate 2025 review confirms the regulatory reality: BPC-157 is not approved by the FDA or other authorities for human use, largely because the comprehensive human studies don’t exist — yet it’s openly sold on dozens of websites.²

Two newer reviews explain why the gap hasn’t closed. A 2025 scoping review from a musculoskeletal group maps the mechanisms — angiogenesis, nitric-oxide signalling, fibroblast activation, all plausible for tendon and muscle — and then notes the same thing: broad preclinical promise, only three small human pilot studies (the knee series, one in bladder pain, one intravenous safety study), and “regulatory controversies” around a compound that is nonetheless widely available.¹⁰ A 2026 pharmaceutical-development review is blunter still: after more than thirty years of animal work there is no approved formulation, no validated dosing regimen and no completed phase 2 trial — the entire human dataset is fewer than 30 people across three uncontrolled pilots — and the peptide’s pharmacokinetics barely match its reported effects — a disconnect that normally stops a drug programme.¹¹ The reason the human studies don’t exist is not that nobody has noticed BPC-157; it’s that it hasn’t cleared the hurdles a real drug has to.

The animal results are genuinely interesting, and it’s fair to say so. But “it heals tendons in rats” and “it’s safe and effective in you” are separated by exactly the human evidence that hasn’t been collected.

Evidence grade: preclinical only. Promising in animals, essentially untested in humans, zero clinical safety data.

TB-500: even thinner for the use it’s sold for

TB-500 is a synthetic fragment marketed off thymosin beta-4, and it’s sold to athletes for muscle and tendon repair. Look at where the actual human research points, though, and it’s somewhere else entirely: the human trials of thymosin beta-4 target heart-attack recovery and corneal (eye) wound healing — serious medical uses run by biotech companies — while the muscle, tendon and “regeneration” evidence sits in animal and embryonic models.³ In other words, there is no human musculoskeletal trial behind the specific injuries people are buying TB-500 to fix. The mechanism is real biology; the gym application is an extrapolation across a species gap.

Evidence grade: preclinical for musculoskeletal use. Human trials exist, but for cardiac and eye conditions — not the sports injuries it’s sold for.

The growth-hormone peptides: they work on hormones, not on the goal

CJC-1295, ipamorelin and MK-677 (ibutamoren) are different — they do have human data, and they do what they claim to your bloodwork. CJC-1295 produced 2- to 10-fold rises in growth hormone and 1.5- to 3-fold rises in IGF-1 in healthy adults.⁴ The catch is that moving a hormone is not the same as delivering the outcome. In the cleanest evidence we have — a two-year randomised trial of MK-677 in healthy adults — the drug raised GH and IGF-1 into the young-adult range and added about 1.1 kg of fat-free mass, but that extra mass produced no measurable gain in strength or physical function.⁶ And it wasn’t free: fasting blood glucose rose and insulin sensitivity fell.⁶ A review of the whole class flags exactly this insulin-sensitivity concern, plus how few long-term safety studies exist.⁵

Ipamorelin, the one most often sold as the “clean” GH peptide, has exactly one placebo-controlled human trial — and it wasn’t in athletes. A phase 2 study gave it intravenously to 114 patients after bowel surgery to speed gut recovery; it was well tolerated and did nothing: no difference from placebo on the main endpoint or any secondary one.¹³ That doesn’t prove it can’t build muscle. It does mean the only controlled human test of ipamorelin failed, and the gym claims rest on its receptor pharmacology, not on a trial.

It’s worth knowing what approval-grade evidence for a growth-hormone-releasing peptide actually looks like, because one exists: tesamorelin, a prescription GHRH analogue licensed for abdominal fat in HIV-associated lipodystrophy. Five randomised trials, pooled, show it reliably cuts visceral fat and liver fat in that patient group.¹⁴ That’s the bar — multiple RCTs, a defined patient population, a regulator’s sign-off, a prescription. None of the vial peptides is anywhere near it.

For a natural athlete, that’s a poor trade: a scan number goes up, the thing you actually care about doesn’t, and your metabolic health goes the wrong way.

Evidence grade: moderate for hormone effects; weak-to-negative for real performance benefit; genuine metabolic downside.

The part the hype never mentions: the risk is entirely the client’s

Strip away the biochemistry and this is, for a coach, mostly a risk conversation. Three things are true at once. It’s unapproved and unregulated — no health authority has cleared these for human use, and grey-market vials carry real contamination and dosing uncertainty.² The long-term safety is unknown — a documented case of MK-677 stacked with a SARM showed body-composition gains alongside a 205% jump in the liver enzyme ALT, crashed testosterone and worsened lipids, a vivid reminder of how these compounds behave in the wild.⁷ And it’s banned in tested sport — anti-doping laboratories have developed and validated blood tests specifically to catch these peptides, so a tested athlete is risking a sanction on top of the health unknowns.⁸⁹

None of that is a reason to shame a curious client — it’s the reason to be the person who lays it out straight before they order a vial.

What the registry is actually testing

Here’s a detail that reframes the whole category. The trial registry lists only about two dozen studies across these peptides — and when you read them, they’re overwhelmingly for medical conditions (heart attack, post-operative ileus, corneal wounds, HIV-associated fat changes), run by pharmaceutical companies, with several withdrawn or terminated before completing.¹⁵ What you do not find is a robust pipeline testing these as muscle-building or injury-recovery aids in healthy athletes. The gym use is running years ahead of the science, on evidence borrowed from entirely different diseases.

Your script for Monday

When a client asks whether they should try BPC-157 or “the GH peptides,” here’s the whole thing:

“Quick check first — you don’t mean collagen powder, you mean the injectable stuff? Okay. Honest answer: the human research on these basically hasn’t been done yet. BPC-157 is almost entirely animal studies — thirty-five to one in the sports-medicine review, and the one is a phone survey of sixteen people; across every use there are fewer than thirty people in uncontrolled pilots — with no controlled safety data in humans. TB-500’s human trials are for heart attacks, not tendons. The growth-hormone ones do raise your hormones, but the best long study showed more mass with no extra strength and worse blood sugar. On top of that they’re unapproved, you can’t be sure what’s actually in the vial, and they’re banned if you ever get tested. I’m not here to judge you for asking — I’m here to make sure you know that the person taking all the risk is you, on evidence that mostly isn’t there yet. Let’s put that energy into the things we know work.”

No fear-mongering, no cheerleading. Just the evidence — including its absence — translated into a decision a client can actually make. That’s the entire job.

Sqwod reads the research so your clients don’t have to. This is coaching and safety information, not medical advice, and it is not an endorsement to use any substance discussed; several are unapproved drugs and decisions about them belong with a qualified doctor. Spotted something that needs sharpening? That’s how an evidence page stays honest — tell us and we’ll correct it in public.